|
|
|
Volumn 8, Issue 9, 2002, Pages 2820-2827
|
|
Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1,25 DIHYDROXYERGOCALCIFEROL;
AMINO TERMINAL TELOPEPTIDE;
BIOLOGICAL MARKER;
CALCIUM;
CARBOXY TERMINAL TELOPEPTIDE;
DOXERCALCIFEROL;
DRUG METABOLITE;
HORMONE;
OSTEOCALCIN;
PARATHYROID HORMONE;
PHOSPHORUS;
PROSTATE SPECIFIC ANTIGEN;
UNCLASSIFIED DRUG;
VITAMIN D DERIVATIVE;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BLOOD LEVEL;
BONE METABOLISM;
CALCIUM EXCRETION;
CALCIUM URINE LEVEL;
CANCER CHEMOTHERAPY;
CANCER HORMONE THERAPY;
CANCER RESISTANCE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE ASSOCIATION;
DISEASE COURSE;
DISEASE MARKER;
DRUG EFFECT;
DRUG RESPONSE;
DRUG TOLERABILITY;
DRUG URINE LEVEL;
DRUG WITHDRAWAL;
HUMAN;
HYPERCALCEMIA;
KIDNEY FAILURE;
MALE;
MAXIMUM TOLERATED DOSE;
PARATHYROID HORMONE BLOOD LEVEL;
PHASE 1 CLINICAL TRIAL;
PHOSPHATE BLOOD LEVEL;
PRIORITY JOURNAL;
PROSTATE CANCER;
VITAMIN BLOOD LEVEL;
ADENOCARCINOMA;
AGED;
AGED, 80 AND OVER;
ANTIGENS, NEOPLASM;
ANTINEOPLASTIC AGENTS, HORMONAL;
CALCIUM;
COHORT STUDIES;
DRUG RESISTANCE, NEOPLASM;
ERGOCALCIFEROLS;
HUMANS;
HYPERCALCEMIA;
KIDNEY FAILURE, CHRONIC;
MALE;
MIDDLE AGED;
NEOPLASM PROTEINS;
OSTEOCALCIN;
PARATHYROID HORMONE;
PHOSPHORUS;
PRODRUGS;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
SALVAGE THERAPY;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 0036716825
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (67)
|
|
References (33)
|
